1. In Vivo
  2. >>Archive

At AAOS, Large Joint Makers Are Making It Personal

At AAOS’ 2012 meeting, one attention-grabbing strategy centered on the personalization of large joint implants to match the specific anatomies of patients. Several large joint manufacturers have introduced tools for achieving “custom fits” for new joints, knees in particular. Advances in robotics and customized manufacturing are enabling smaller companies to take personalization to the next step. MAKO featured its MAKOplasty Total Hip Arthroplasty (MAKOplasty THA), an advancement of its partial knee MAKOplasty procedure. In another approach toward customizing knee surgeries, ConforMIS manufactures a line of knee implants that are custom made for each individual patient.

Over the past few quarters, large joint manufacturers have been reporting stable but relatively flat sales growth, forcing makers of hip and knee implants to try to grab market share from rivals. Traditionally, this isn’t an easy task as large joint surgeons are notoriously loyal to their favorite implants, so medical device manufacturers continue to pursue new techniques and approaches to help them win over surgeons and purchasing hospitals.

At last month’s American Academy of Orthopaedic Surgeons 2012 Annual Meeting, one attention-grabbing strategy centered on the personalization of large...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.